Skip to main content
RecallFDAfda-F-0321-2025UNDECLARED ALLERGEN

An Pan bun is a sweet roll filled with sweet red bean paste, stamped with black sesame seeds on top. Product is packaged in clear polypro...

Category
Units Affected
115
Recall Date
November 27, 2024
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0321-2025.

The contains statement does not declare sesame. Black sesame seeds are visible on product and the Ingredients Statement declares black sesame seeds.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0321-2025.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Oyatsupan Bakers or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0321-2025.

OYATSUPAN BAKERS

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Oyatsupan Bakers Recall FAQ

Oyatsupan Bakers is the subject of a dairy safety report: An Pan bun is a sweet roll filled with sweet red bean paste, stamped with black sesame seeds on top. Product is packaged in clear polypro.... The notice was published on November 27, 2024 by the U.S. Food and Drug Administration (FDA). Approximately 115 units are potentially affected.